EGFR and neoplasm: Interestingly, anti-EGFR sensitization of IGORV-1 for 7 days resulted in significantly enhanced NK cytotoxicity (Figure 2c) and increased NK-specific tumor cell lysis (Figure 2d) in the presence of cetuximab.